MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
MOLECULAR PARTNERS AG
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 12, 2026
$3.66+0.10 (+2.81%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | 3.08 | 8.79 | |
| Interest coverage | – | -12.1× | -11.5× | |
| Capex to revenue | – | 15.5% | – | |
| Diluted shares | – | 25M | 37M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Molecular Partners generated CHF 379.03M from operations and spent CHF 4.74M on capital expenditure, dividends and share buybacks. 87% of that went back into the business.
Generated
CHF 379.03M
Used
CHF 4.74M
Capital expenditureCHF 4.10M87%DividendsCHF 00%Share buybacksCHF 631.00K13%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 4 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-CHF 51.26M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-CHF 51.26M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose14.31 → 8.79
- No dilutionShare count did not rise34M → 37M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.03 → 0.00